Skip to main content
Ajanta Pharma Ltd. logo

Ajanta Pharma Ltd. — Investor Relations & Filings

Ticker · AJANTPHARM ISIN · INE031B01049 LEI · 3358008XLYJJZBFBCK12 BSE.NS Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2020-07-30 Regulatory Filings
Country IN India
Listing BSE.NS AJANTPHARM

About Ajanta Pharma Ltd.

https://www.ajantapharma.com

Ajanta Pharma Ltd. is a specialty pharmaceutical organization engaged in the development, manufacturing, and marketing of high-quality finished dosage formulations. The company maintains a significant presence in specialized therapeutic segments, including ophthalmology, dermatology, cardiology, and pain management. It operates advanced research and development centers dedicated to creating complex generics and first-to-market products. With a global footprint, the firm serves diverse healthcare needs across the United States and various emerging markets in Asia and Africa. Its manufacturing infrastructure comprises multiple state-of-the-art facilities designed to meet international regulatory standards, ensuring the delivery of effective and affordable healthcare solutions. The company's strategic focus remains on niche product categories and branded generics, supported by a robust supply chain and a commitment to innovation in drug delivery systems.

Recent filings

Filing Released Lang Actions
Financial Result Updates
Regulatory Filings
2020-07-30 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a compliance notice under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about the publication of a notice regarding a Board of Directors meeting scheduled for July 30, 2020. The document includes details about the meeting announcement published in newspapers and is addressed to stock exchanges. There is no substantive financial data, financial statements, or detailed report content present. The document is essentially an announcement of a forthcoming board meeting and related compliance information, not the actual report or financial results. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2020-07-21 English
Board Meeting — Financial Results
Board/Management Information Classification · 95% confidence The document is a short notice informing the stock exchanges about an upcoming Board meeting to consider and approve unaudited financial results for the first quarter ended June 30, 2020. It is a notification of a meeting rather than the financial results themselves or a detailed report. The document length is only 1191 characters, indicating it is a brief announcement. According to the rules, such a notice about a Board meeting to approve financial results fits best under Board/Management Information (MANG), as it announces a board meeting and management activity rather than the financial report itself or earnings release.
2020-07-20 English
Updates
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 30 June 2020. It is issued by the Registrar and Share Transfer Agent certifying dematerialization and cancellation of securities and substitution of the depository name. The document is a compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements or substantive financial data. It is also not an announcement of voting results, board changes, or capital changes. Given the nature of the document as a regulatory compliance certificate, it fits best under Regulatory Filings (RNS). The document length is short (2288 characters), and it is a formal certification letter, not a report or announcement of a report.
2020-07-15 English
Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India regarding the impact of COVID-19 on the company's business operations. It provides detailed disclosures about the pandemic's effect on various operational and financial parameters but does not contain any financial statements, audit opinions, or comprehensive financial data. The letter is a regulatory communication responding to a query or requirement from the stock exchange, providing updates and clarifications. It is not an annual report, interim report, earnings release, or any other formal financial report. The document is a regulatory filing or announcement related to compliance and disclosure obligations. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2020-07-13 English
Copy of Newspaper Publication
Regulatory Filings
2020-07-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.